Eli Lilly, Zepbound
Digest more
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.